In vitro activity of doripenem in combination with various antimicrobials against multidrug-resistant acinetobacter baumannii: Possible options for the treatment of complicated infection

Microbial Drug Resistance

Volumn 19, Issue 5, 2013, Pages 407-414

  Principe, Luigi ^a   Capone, Alessandro ^b   Mazzarelli, Antonio ^b   D'Arezzo, Silvia ^b   Bordi, Eugenio ^b   Di Caro, Antonino ^b   Petrosillo, Nicola ^b  

^a A MANZONI HOSPITAL   (Italy)

^b NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; COLISTIN; DORIPENEM; RIFAMPICIN; SULTAMICILLIN; TIGECYCLINE;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATE; COMBINATION CHEMOTHERAPY; DRUG INDICATION; DRUG POTENTIATION; IN VITRO STUDY; INFECTION COMPLICATION; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; AMIKACIN; ANTI-BACTERIAL AGENTS; CARBAPENEMS; COLISTIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HUMANS; INTENSIVE CARE UNITS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; TERTIARY HEALTHCARE;

EID: 84884568940     PISSN: 10766294     EISSN: 19318448     Source Type: Journal    
DOI: 10.1089/mdr.2012.0250     Document Type: Article

References (30)

1. Bowker, K.E., A.R. Noel, S.G. Tomaselli, H. Elliott, and A.P. Macgowan. 2012. Pharmacodynamics of the antibacterial effect and emergence of resistance to doripenem in Pseudomonas aeruginosa and Acinetobacter baumannii studied in an in vitro pharmacokinetic model. Antimicrob. Agents Chemother. 56:5009-5015
2. Cai, Y., D. Chai, R. Wang, B. Liang, and N. Bai. 2012. Colistin resistance of Acinetobacter baumannii: Clinical reports, mechanisms and antimicrobial strategies. J. Antimicrob. Chemother. 67:1607-1615
3. Capone, A., S. D'Arezzo, P. Visca, and N. Petrosillo. 2008. In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii. J. Antimicrob. Chemother. 62: 422-423
4. CLSI] Clinical and Laboratory Standards Institute. 2009. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved Standard-Eighth edition. CLSI document M07-A8. Wayne, PA: CLSI
5. CLSI] Clinical and Laboratory Standards Institute. 2010. Performance standards for antimicrobial susceptibility testing. Twentieth informational supplement. CLSI document M100-S20. Wayne, PA: CLSI
6. Cunha, B.A. 2006. New uses for older antibiotics: Nitrofurantoin, amikacin, colistin, polymyxin B, doxycycline, and minocycline revisited. Med. Clin. North Am. 90: 1089-1107
7. D'Arezzo, S., A. Capone, N. Petrosillo, and P. Visca. 2009. Epidemic multidrug-resistant Acinetobacter baumannii related to European clonal types I and II in Rome (Italy). Clin. Microbiol. Infect. 15:347-357
8. D'Arezzo, S., L. Principe, A. Capone, N. Petrosillo, A. Petrucca, and P. Visca. 2011. Changing carbapenemase gene pattern in an epidemic multidrug-resistant Acinetobacter baumannii lineage causing multiple outbreaks in central Italy. J. Antimicrob. Chemother. 66:54-61
9. Entenza, J.M., and P. Moreillon. 2009. Tigecycline in combination with other antimicrobials: A review of in vitro, animal and case report studies. Int. J. Antimicrob. Agents 34: 8.e1-e9
10. Falagas, M.E., and D.E. Karageorgopoulos. 2008. Pandrug resistance (PDR), extensive drug resistance (XDR), and multidrug resistance (MDR) among Gram-negative bacilli: Need for international harmonization in terminology. Clin. Infect. Dis. 46:1121-1122
11. Higgins, P.G., C. Dammhayn, M. Hackel, and H. Seifert. 2010. Global spread of carbapenem-resistant Acinetobacter baumannii. J. Antimicrob. Chemother. 65:233-238
12. Hogg, G.M., J.G. Barr, and C.H. Webb. 1998. In-vitro activity of the combination of colistin and rifampicin against multidrug-resistant strains of Acinetobacter baumannii. J. Antimicrob. Chemother. 41:494-495
13. Iacono, M., L. Villa, D. Fortini, R. Bordoni, F. Imperi, R.J. Bonnal, T. Sicheritz-Ponten, G. De Bellis, P. Visca, A. Cassone, and A. Carattoli. 2008. Whole-genome pyrosequencing of an epidemic multidrug-resistant Acinetobacter baumannii strain belonging to the European clone II group. Antimicrob. Agents Chemother. 52:2616-2625
14. Kempf, M., and J.M. Rolain. 2012. Emergence of resistance to carbapenems in Acinetobacter baumannii in Europe: Clinical impact and therapeutic options. Int. J. Antimicrob. Agents 39:105-114
15. Kiratisin, P., A. Apisarnthanarak, and S. Kaewdaeng. 2010. Synergistic activities between carbapenems and other antimicrobial agents against Acinetobacter baumannii including multidrug-resistant and extensively drug-resistant isolates. Int. J. Antimicrob. Agents 36:243-246
16. Kiratisin, P., A. Chongthaleong, T.Y. Tan, E. Lagamayo, S. Roberts, J. Garcia, and T. Davies. 2012. Comparative in vitro activity of carbapenems against major Gram-negative pathogens: Results of Asia-Pacific surveillance from the COMPACT II study. Int. J. Antimicrob. Agents 39:311-316
17. Marti, S., J. Sánchez-Céspedes, V. Alba, and J. Vila. 2009. In vitro activity of doripenem against Acinetobacter baumannii clinical isolates. Int. J. Antimicrob. Agents 33:181-182
18. Meagher, A.K., P.G. Ambrose, T.H. Grasela, and E.J. Ellis-Grosse. 2005. The pharmacokinetic and pharmacodynamic profile of tigecycline. Clin. Infect. Dis. 41:333-340
19. Navon-Venezia, S., A. Leavitt, and Y. Carmeli. 2007. High tigecycline resistance in multidrug-resistant Acinetobacter baumannii. J. Antimicrob. Chemother. 59:772-774
20. Nemec, A., L. Dijkshoorn, and T.J. van der Reijden. 2004. Long-Term predominance of two pan-European clones among multi-resistant Acinetobacter baumannii strains in the Czech Republic. J. Med. Microbiol. 53:147-153
21. Pankuch, G.A., H. Seifert, and P.C. Appelbaum. 2010. Activity of doripenem with and without levofloxacin, amikacin, and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii. Diagn. Microbiol. Infect. Dis. 67: 191-197
22. Paterson, L.R. 2008. Areview of tigecycline-The first glycylcycline. Int. J. Antimicrob. Agents 32:215-222
23. Petersen, P.J., P. Labthavikul, C.H. Jones, and P.A. Bradford. 2006. In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysis. J. Antimicrob. Chemother. 57:573-576
24. Petrosillo, N., E. Ioannidou, and M.E. Falagas. 2008. Colistin monotherapy vs. combination therapy: Evidence from microbiological, animal and clinical studies. Clin. Microbiol. Infect. 14:816-827
25. Principe, L., S. D'Arezzo, A. Capone, N. Petrosillo, and P. Visca. 2009. In vitro activity of tigecycline in combination with various antimicrobials against multidrug resistant Acinetobacter baumannii. Ann. Clin. Microbiol. Antimicrob. 8:18
26. Reid, G.E., S.A. Grim, C.A. Aldeza, W.M. Janda, and N. Clark. 2007. Rapid development of Acinetobacter baumannii resistance to tigecycline. Pharmacotherapy 27:1198-1201
27. Scheetz, M.H., C. Qi, J.R. Warren, M.J. Postelnick, T. Zembower, A. Obias, and G.A. Noskin. 2007. In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 51: 1621-1626
28. Stroup, J.S., K. Mitchell, and D. Hitzeman. 2010. Novel treatment approach to combat an infection with Acinetobacter. Proc. (Bayl. Univ. Med. Cent.) 23:29-30
29. Taneja, N., G. Singh, M. Singh, and M. Sharma. 2011. Emergence of tigecycline & colistin resistant Acinetobacter baumannii in patients with complicated urinary tract infections in north India. Indian J. Med. Res. 133:681-684
30. Visca, P., H. Seifert, and K.J. Towner. 2011. Acinetobacter infection-An emerging threat to human health. IUBMB Life 63:1048-1054